内镜经蝶手术时代巨大垂体腺瘤的治疗策略:多中心系列研究
该多中心回顾性病例对照系列纳入64例最大径≥4 cm且体积≥10 cm³的巨大垂体腺瘤患者,评估内镜经蝶手术(ETS)时代的治疗策略与结局。所有患者初次手术均为ETS,总全切除率在圆形腺瘤为64%、哑铃形46%、多叶形8%(p<0.001)。按切除程度分组后,残余模式指导后续治疗,包括早期开颅再手术、延迟内镜/开颅再手术及辅助放射外科。
要点
- 巨大垂体腺瘤的全切除率与形态相关:圆形64%、哑铃形46%、多叶形8%。
- 残余位于颅内者需警惕出血转化,本组14%需早期开颅再手术。
- 随访平均3年,91%病例达到疾病稳定,本系列无死亡。
核心结论
- ETS作为巨大垂体腺瘤缓解占位效应的首选治疗,切除程度取决于腺瘤形态。
- 残余垂体腺瘤的模式可指导后续治疗策略,包括早期开颅再手术、延迟内镜经蝶/开颅再手术及辅助放射外科。
研究设计与样本
- 回顾性病例对照系列,纳入64例巨大垂体腺瘤患者,来自两个三级医疗中心、由具备ETS经验的外科医生治疗。
- 巨大垂体腺瘤定义为术前等体素增强MRI上最大径≥4 cm且体积≥10 cm³。
主要发现
- 所有病例初次手术均为ETS。
- 总全切除率:圆形腺瘤64%,哑铃形46%,多叶形8%(p<0.001)。
- 按切除程度分组:A组(全切除或部分切除伴海绵窦内残余)21/64(33%),B组(部分切除伴颅内残余)43/64(67%)。
- A组中腺瘤形态多为圆形(11/14,79%),B组多为多叶形(33/37,89%)。
- A组无患者需二次手术,2/21(9%)接受辅助放射外科;B组中6/43(14%)因残余出血转化需早期开颅再手术,其余B组残余患者中5/43(12%)行开颅手术、12/43(28%)行延迟二次ETS。
临床怎么用
- 术前根据腺瘤形态(圆形、哑铃形、多叶形)预判全切除可能性并制定个体化策略。
- 对颅内残余尤其需警惕出血转化,必要时早期开颅再手术。
- 对海绵窦内残余或延迟残余可选择辅助放射外科或延迟二次经蝶/开颅手术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Given the anatomical complexity and frequently invasive growth of giant pituitary adenomas (GPAs), individually tailored approaches are required. The aim of this study was to assess the treatment strategies and outcomes in a large multicenter series of GPAs in the era of endoscopic transsphenoidal surgery (ETS). METHODS: This was a retrospective case-control series of 64 patients with GPAs treated at two tertiary care centers by surgeons with experience in ETS. GPAs were defined by a maximum diameter of ≥ 4 cm and a volume of ≥ 10 cm3 on preoperative isovoxel contrast-enhanced MRI. RESULTS: The primary operation was ETS in all cases. Overall gross-total resection rates were 64% in round GPAs, 46% in dumbbell-shaped GPAs, and 8% in multilobular GPAs (p < 0.001). Postoperative outcomes were further stratified into two groups based on extent of resection: group A (gross-total resection or partial resection with intracavernous remnant; 21/64, 33%) and group B (partial resection with intracranial remnant; 43/64, 67%). Growth patterns of GPAs were mostly round (11/14, 79%) in group A and multilobular (33/37, 89%) in group B. In group A, no patients required a second operation, and 2/21 (9%) were treated with adjuvant radiosurgery. In group B, early transcranial reoperation was required in 6/43 (14%) cases due to hemorrhagic transformation of remnants. For the remaining group B patients with remnants, 5/43 (12%) underwent transcranial surgery and 12/43 (28%) underwent delayed second ETS. There were no deaths in this series. Severe complications included stroke (6%), meningitis (6%), hydrocephalus requiring shunting (6%), and loss or distinct worsening of vision (3%). At follow-up (mean 3 years, range 0.5-16 years), stable disease was achieved in 91% of cases. CONCLUSIONS: ETS as a primary treatment modality to relieve mass effect in GPAs and extent of resection are dependent on GPA morphology. The pattern of residual pituitary adenoma guides further treatment strategies, including early transcranial reoperation, delayed endoscopic transsphenoidal/transcranial reoperation, and adjuvant radiosurgery.
引用
- Micko A, Agam MS, Brunswick A, et al. Treatment strategies for giant pituitary adenomas in the era of endoscopic transsphenoidal surgery: a multicenter series. J Neurosurg. 2021. PMID: 34388714. doi:10.3171/2021.1.JNS203982
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。